lilly
Lilly posts strong quarterly results, faces challenges ahead
July 22, 2011Sales and Marketing lilly, patent expiry
Lilly edged toward double-digit growth in the second quarter, but looming patent expires threaten this trend. Second quarter revenue grew …
Lilly presents data on failed Alzheimer’s candidate
July 21, 2011Research and Development Alzheimer's disease, lilly, research and development news, semagacestat
Lilly has presented a review of data from semagacestat, the Alzheimer’s drug it dropped last year after disappointing results. Phase …
Lilly chief: German reforms jeopardise pharma innovation
July 8, 2011Research and Development, Sales and Marketing Germany, John Lechleiter, lilly, medicines pricing
German healthcare spending cuts have gone too far and risk jeopardising pharmaceutical innovation in the country, according to Lilly’s chief …
Lilly prepares late-stage pipeline boost
July 1, 2011Research and Development, Sales and Marketing autoimmune diseases, diabetes, lilly, neuroscience, oncology
Eli Lilly has highlighted diabetes, oncology, autoimmune diseases and neuroscience as key therapy areas within its growth strategy. Within these …
Boehringer-Lilly launch diabetes drug Tradjenta in US
June 16, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …
Lilly cuts jobs in Ireland
May 23, 2011Manufacturing and Production Ireland, job cuts, lilly, manufacturing and production
Eli Lilly has said it is downsizing its plant in County Cork, Ireland, by around 14% in light of patent …
Lilly accused of anti-competitive practices
May 17, 2011Amylin, Boehringer, diabetes, exenatide, lilly, linagliptin
Amylin Pharmaceuticals is suing Eli Lilly and Company for alleged anticompetitive activity around Lilly’s January agreement with Boehringer Ingelheim to …
US approval for Boehringer’s diabetes drug Tradjenta
May 3, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Lilly hails progress of new R&D approaches
February 16, 2011Research and Development, Sales and Marketing Chorus, Mirror Portfolio, R&D, lilly
Lilly says two of its experimental approaches to re-designing R&D are beginning to pay off.Like all of its peers, the …
Lilly chief issues warning on UK reforms
February 11, 2011Research and Development, Sales and Marketing John Lechleiter, US health reforms, healthcare reform, lilly, patent box, value-based pricing
Lilly chief executive John Lechleiter has warned that two key UK initiatives could fall seriously short of encouraging investment in …
Innovation is being stifled – Lilly chief executive
February 10, 2011Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly
Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
Lilly Oncology chief resigns
January 27, 2011Research and Development, Sales and Marketing Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing
Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …
Diabetes drugs show promise in Alzheimer’s
January 17, 2011Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide
Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
